|
1
|
Perl A, Fernandez DR, Telarico T, Doherty
E, Francis L and Phillips PE: T-cell and B-cell signaling
biomarkers and treatment targets in lupus. Curr Opin Rheumatol.
21:454–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dooley MA, Hogan S, Jennette C and Falk R;
Glomerular Disease Collaborative Network. Cyclophosphamide therapy
for lupus nephritis: poor renal survival in black Americans. Kidney
Int. 51:1188–1195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Monneaux F and Muller S: Molecular
therapies for systemic lupus erythematosus: clinical trials and
future prospects. Arthritis Res Ther. 11:2342009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuryłowicz A and Nauman J: The role of
nuclear factor-kappaB in the development of autoimmune diseases: a
link between genes and environment. Acta Biochim Pol. 55:629–647.
2008.PubMed/NCBI
|
|
5
|
Moynagh PN: The NF-kappaB pathway. J Cell
Sci. 118:4589–4592. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalergis AM, Iruretagoyena MI, Barrientos
MJ, et al: Modulation of nuclear factor-kappaB activity can
influence the susceptibility to systemic lupus erythematosus.
Immunology. 128(1 Suppl): e306–e314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feng D, Yang L, Bi X, Stone RC, Patel P
and Barnes BJ: Irf5-deficient mice are protected from
pristane-induced lupus via increased Th2 cytokines and altered IgG
class switching. Eur J Immunol. 42:1477–1487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohsugi T, Horie R, Kumasaka T, et al: In
vivo antitumor activity of the NF-kappaB inhibitor
dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell
leukemia. Carcinogenesis. 26:1382–1388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wellmann U, Letz M, Schneider A, Amann K
and Winkler TH: An Ig mu-heavy chain transgene inhibits systemic
lupus erythematosus immunopathology in autoimmune (NZB × NZW)F1
mice. Int Immunol. 13:1461–1469. 2001.PubMed/NCBI
|
|
10
|
Comby E, Tanaff P, Mariotte D,
Costentin-Pignol V, Marcelli C and Ballet JJ: Evolution of
antinuclear antibodies and clinical patterns in patients with
active rheumatoid arthritis with longterm infliximab therapy. J
Rheumatol. 33:24–30. 2006.PubMed/NCBI
|
|
11
|
Hoffmann A, Kerr S, Jellusova J, et al:
Siglec-G is a B1 cell-inhibitory receptor that controls expansion
and calcium signaling of the B1 cell population. Nat Immunol.
8:695–704. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niculescu F, Nguyen P, Niculescu T, Rus H,
Rus V and Via CS: Pathogenic T cells in murine lupus exhibit
spontaneous signaling activity through phosphatidylinositol
3-kinase and mitogen-activated protein kinase pathways. Arthritis
Rheum. 48:1071–1079. 2003. View Article : Google Scholar
|
|
13
|
Matsumoto N, Ariga A, To-e S, et al:
Synthesis of NF-kappaB activation inhibitors derived from
epoxyquinomicin C. Bioorg Med Chem Lett. 10:865–869. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsumoto N, Iinuma H, Sawa T, et al:
Epoxyquinomicins A, B, C and D, new antibiotics from
Amycolatopsis. II Effect on type II collagen-induced
arthritis in mice. J Antibiot (Tokyo). 50:906–911. 1997.PubMed/NCBI
|
|
15
|
Ariga A, Namekawa J, Matsumoto N, Inoue J
and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced
nuclear translocation and activation of NF-kappa B by
dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iruretagoyena MI, Tobar JA, González PA,
et al: Andrographolide interferes with T cell activation and
reduces experimental autoimmune encephalomyelitis in the mouse. J
Pharmacol Exp Ther. 312:366–372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang T, Tian F, Zheng H, et al: Nrf2
suppresses lupus nephritis through inhibition of oxidative injury
and the NF-κB-mediated inflammatory response. Kidney Int.
85:333–343. 2014.PubMed/NCBI
|
|
19
|
Brown KD, Claudio E and Siebenlist U: The
roles of the classical and alternative nuclear factor-kappaB
pathways: potential implications for autoimmunity and rheumatoid
arthritis. Arthritis Res Ther. 10:2122008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mavropoulos A, Rigopoulou EI, Liaskos C,
Bogdanos DP and Sakkas LI: The role of p38 MAPK in the
aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev
Immunol. 2013:5697512013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin N, Wang Q, Zhang X, Jiang D, Cheng H
and Zhu K: The selective p38 mitogen-activated protein kinase
inhibitor, SB203580, improves renal disease in MRL/lpr mouse model
of systemic lupus. Int Immunopharmacol. 11:1319–1326. 2011.
View Article : Google Scholar : PubMed/NCBI
|
